People in the News

Premium

Merck said that its directors have nominated Thomas Cech to join the company's board.

Cech, who will stand for election by Merck shareholders in April, is currently president of the Howard Hughes Medical Institute. He is slated to step down from the position in March, when he will return to a faculty position at the University of Colorado, Boulder.

Cech is a co-founder of Ribozyme Pharmaceuticals, which later became Sirna Therapeutics. Merck acquired Sirna in 2006.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Two new Reproducibility Project: Cancer Biology studies have largely reproduced the original findings, ScienceInsider reports.

DNA fingerprinting could catch some sample mix-ups at pathology labs, the New York Times says.

A Maryland police department has turned to DNA phenotyping to develop a suspect sketch, WJLA reports.

In Cell this week: DNA methylation and T cell exhaustion, longevity in C. elegans, and more.